Literature DB >> 16170667

Kinetics of marked development of lung metastasis of rat prostatic carcinomas transplanted in syngeneic rats.

Laiyuan Zhao1, Mitsuru Futakuchi, Shugo Suzuki, Yoshiaki Ohhara, Takashi Hashimoto, Tatsuya Suzuki, Tadao Manabe, Tomoyuki Shirai.   

Abstract

In order to investigate how and when metastases develop under experimental conditions, kinetics of the size and the number of lung metastasis lesions in F344 rats were examined after syngeneic transplantation of rat prostate carcinomas induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB). Cell proliferation of the subcutaneous tumor and lung metastatic lesions was evaluated along with the expression of VEGF-A splicing variants and endostatin, serum VEGF levels and vascular density in the tumor. Several pieces of tumor tissue were introduced subcutaneously into two different sites on the dorsal side of F344 rats through a 14G needle. Average body weight of recipient rats markedly decreased despite only a gradual increase in tumor volume. The absolute total number of metastatic lesions in rats (n=5) were 2, 10, 19 and 194 at weeks 7.5, 9, 11 and 13, respectively, and a notable increase was observed at week 13. Similarly, the mitotic index of lung metastatic lesions increased remarkably at week 9 while the mitotic index and apoptotic index of transplanted tumors did not change throughout the experimental period. Expression of VEGF-A121, A164, A188 and endostatin, serum VEGF levels and vascular density did not correlate with the spread of lung lesions. In conclusion, both the number and the size of metastatic lesions increased at the same time after a notable increase in cell proliferation. Factors other than VEGF or endostatin may be involved in the mechanism of explosive lung metastasis spread.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170667     DOI: 10.1007/s10585-005-0054-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  32 in total

Review 1.  Cancer metastasis: a search for therapeutic inhibition.

Authors:  C J Dimitroff; A Sharma; R J Bernacki
Journal:  Cancer Invest       Date:  1998       Impact factor: 2.176

2.  Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.

Authors:  M Asamoto; N Hokaiwado; Y M Cho; S Takahashi; Y Ikeda; K Imaida; T Shirai
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

3.  Tumor angiogenesis and tissue factor.

Authors:  J Folkman
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

4.  Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas.

Authors:  I Ding; J Z Sun; B Fenton; W M Liu; P Kimsely; P Okunieff; W Min
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

5.  Endostatin induces autophagic cell death in EAhy926 human endothelial cells.

Authors:  Y-P Chau; S-Y Lin; J H-C Chen; M-H Tai
Journal:  Histol Histopathol       Date:  2003-07       Impact factor: 2.303

Review 6.  Angiogenesis inhibitors in clinical development for lung cancer.

Authors:  Roy S Herbst; Manuel Hidalgo; A Scott Pierson; Scott N Holden; Michael Bergen; S Gail Eckhardt
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

Review 7.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

8.  Promotion of experimental liver metastasis by tumor necrosis factor.

Authors:  P Orosz; A Krüger; M Hubbe; J Rüschoff; P Von Hoegen; D N Männel
Journal:  Int J Cancer       Date:  1995-03-16       Impact factor: 7.396

Review 9.  Development and prevention of metastasis.

Authors:  E C Kohn
Journal:  Anticancer Res       Date:  1993 Nov-Dec       Impact factor: 2.480

10.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.